Positive pre-clinical results for CRISPR-based HIV therapy
The CRISPR-based therapy called EBT-101 excised HIV proviral DNA from the genomes of different cells and tissues in human cells and mice.
List view / Grid view
The CRISPR-based therapy called EBT-101 excised HIV proviral DNA from the genomes of different cells and tissues in human cells and mice.
Scientists targeted a mouse's own cells using a synthetic molecule called EEZE, presenting a novel way to treat pneumonia.
Stealth BioTherapeutic's SBT-272 improved mitochondrial motility in a murine model of amyotrophic lateral sclerosis.
A new study has suggested that mucosal vaccines may reduce transmission of airborne viruses such as COVID-19 more than injectable vaccines.
Axitinib, a common chemotherapy drug, restored memory and cognitive function in mouse models, representing a potential Alzheimer’s treatment.
Lipophosphonoxins may represent the next generation of antibiotics and can be delivered using a new type of dressing for skin wounds.
Stealth BioTherapeutics reported positive data from a pre-clinical study evaluating SBT-272 in a murine model of Parkinson's disease.
New research has revealed that club cells secret anti-immunosuppressive factors in tumours, potentially revolutionising cancer therapies.
A nasal spray of the COVID-19 Vaccine Oxford/AstraZeneca was found to protect hamsters and monkeys against SARS-CoV-2 in an NIH study.
Researchers have found a vulnerability in a developmental signalling pathway, presenting a target for paediatric low-grade glioma formation.
19 August 2021 | By 10X Genomics
Explore the latest developments in screening technologies and how drug discovery has changed during the past decades in our webinar with 10X Genomics.
MIT researchers have shown that a combination of three drugs can eliminate pancreatic tumours in mice, possibly leading to new therapies.
The RNA-modifying protein METTL1 could be targeted to treat some types of aggressive cancers, including brain, blood and kidney.
Scientists from the University of Chicago discovered that the drug masitinib inhibits the replication of SARS-CoV-2 in mice.
Examining existing R&D processes with a consolidated approach enables the stop of disjointed workflows to engage on the digitisation journey.